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Purpose: The selection of surgeons to participate in a prospective randomized trial 
comparing the efficacy of a surgical method with medical management is critically 
important because it will have a direct impact on the outcome of the study and the future 
use of the operation. We report he success of the method used for selecting surgeons who 
participated in the Asymptomatic Carotid Atherosclerosis Study (ACAS) by examining the 
surgical morbidity and mortality rates and the outcome of the study. 
Methods: A Surgical Management Committee stablished criteria for auditing surgeons 
who wished to participate in the study. The parameters included aminimum performance 
of at least 12 carotid endarterectomies (CEA) per year and an audit of each surgeon's last 
50 consecutive CEAs with required ocumentation f a combined neurologic morbidity 
and mortality rate of < 3.0% for asymptomatic patients and < 5.0% for all indications 
including symptomatic patients. 
Results: As of February 1991, 164 surgeons from 48 medical centers applied for ACAS 
participation. One hundred seventeen were approved, and their aggregate experience of 
5641 operations yielded a combined neurologic morbidity and mortality rate of 2.3% for 
asymptomatic and symptomatic patients combined. The morbidity and mortality rate for 
CEA on asymptomatic patients was 1.7%. These surgeons, plus those recruited after 
February 1991, became investigators in the ACAS trial and were responsible for the 
surgical care of 825 patients who were randomized to the surgical arm. Seven hundred 
twenty-four patients actually underwent CEA. One patient (0.14%) died and ten patients 
(1.38%) had strokes within the 30-day perioperative interval, for a combined stroke or 
death incidence of 1.52%. The 5-year stroke event rate in the surgical group (including 
perioperative morbidity and mortality rates) was 5.1%, compared with 11% of patients 
treated medically, yielding a relative risk reduction of 53% in favor of surgery (p = 
0.004). 
Conclusions: A method for selecting surgeons for participation i  the ACAS trial was 
successful in providing low perioperative morbidity and mortality rates. This materially 
influenced the outcome of the study in favor of CEA. (J VASe SURG 1996;23:323-8.) 
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The Asymptomatic Carotid Atherosclerosis 
Study (ACAS) was brought o an early conclusion on 
September 14, 1994, with the issuance of a clinical 
advisory by the National Institutes of  Health that 
stated that a significant boundary had been crossed in 
favor of carotid endarterectomy (CEA). Asymptom- 
atic patients with hemodynamically significant ca- 
rotid stenoses with > 60% diameter reduction had 
fewer strokes when treated with the combination of 
CEA and best medical management (325 mg aspirin 
and risk-factor control) than those treated with best 
medical management alone. 1,2 
In large part this benefit for CEA was made 
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possible by the low morbidity and mortality rates 
accomplished by ACAS-approved surgeons. The 
objective of this report is to describe the method by 
which these surgeons were selected and to determine 
whether the study results justify the methods for 
surgeon selection. 
MATERIALS AND METHODS 
ACAS trial design. The ACAS trial asked the 
following question: Among patients with severe but 
asymptomatic carotid stenoses, does CEA plus medi- 
cal management and risk-factor control reduce the 
overall 5-year risk of fatal and nonfatal ipsilateral 
cerebral events when compared with a similar group 
of patients who are managed only medically? 
Patients with hemodynamically significant ca- 
rotid stenosis determined to be equivalent to a 60% 
diameter-reducing lesion of the internal carotid 
artery were randomly allocated to a surgical or 
medical arm. The design and conduct of the trial have 
been previously described.2,s Primary endpoints were 
any stroke or death after randomization and within 
the 30-day periopcrative period for patients receiving 
CEA, a comparable 42-day period after randomiza- 
tion for those not assigned to surgery, and any 
ipsilateral stroke or stroke-related death that occurred 
during follow-up. Surgically treated patients were 
examined by the neurologist or study coordinator 24 
hours after surgery to determine whether apersistent 
neurologic deficit was present. Patients were exam- 
ined again 30 days after surgery, or 42 days after 
randomization i  the medical group, to determine 
whether aneurologic deficit had occurred within that 
interval. All potential endpoints were reviewed by the 
cerebrovascular cndpoints committee. 
Patients with hemodynamically significant ste- 
noses could be identified in one of three ways: (1) 
conventional or arterial digital subtraction angiogra- 
phy documenting a > 60% diameter-reducing le-
sion, as measured by comparing the minimal residual 
lumen with a normal distal internal carotid artery 
lumen in the equation 1 - (MRL/DL) × 100; (2) 
Doppler ultrasonography documenting a peak- 
systolic frequency or end-diastolic frequency greater 
than a machine-specific cutoff point with a predicted 
false-positive rate of < 5.0%, as determined by previ- 
ous correlation of Doppler flow velocities with arteri- 
ography in 50 consecutive cases; (3) Doppler ultra- 
sonography documenting a peak-systolic frequency 
or end-diastolic frequency greater than a machine- 
specific cutoff point with a predicted < 10% false- 
positive rate, and OPG-GEE examination demon- 
strating pressure reduction > 5.0 mm Hg. Patients 
who were randomized to medical management were 
not required to have a contrast artcriogram. Patients 
randomized to surgery were required to have one 
before surgery if they had not already had an arterio- 
gram performed within 6 months of entering the 
s tudy .  2 
Surgeon selection process. The Executive Com- 
mittee recognized that a critical element for the suc- 
cessful conduct of this study would be the selection of 
highly competent surgeons to perform CEA. Com- 
petence was defined as the ability to perform CEA in 
asymptomatic patients with an acceptably ow mor- 
bidity and mortality rate ( < 3.0%). 
A Surgical Management Committee was formed 
to devise a method for selecting surgeons and to 
oversee the surgical conduct of the protocol (Appen- 
dix 1). The details of that deliberation have been 
published previously and will be briefly reviewed. 4 
As part of the initial process to determine whether 
a clinical center would be qualified to participate in 
the ACAS trial, a review of all CEAs performed at the 
center's affiliated hospitals during the most recent 
1-year interval was required. A data sheet that 
provided etails concerning the patient's history, the 
indication for surgery, whether the pa6ent was 
symptomatic, the scverity of carotid stenosis, and any 
associated complications or death was completed for 
each surgery. A review of these data gave the 
Executive Committee an overall idea of the compli- 
cation rates and the number of potential cases that 
would be fotmd within the center. Once the center 
was deemed to be qualificd, each potential surgeon 
from that center who wished to participate was 
required to submit he results of his or her 50 most 
reccnt consecutive CEAs. This retrospective audit 
permitted the committee to examine operation date, 
indication for operation (asymptomatic, transient 
ischemic attack, stroke), duration of hospitalization, 
and outcome, especially with regard to whether 
postoperative d ath or stroke occurred. 
The members of the Surgical Management Com- 
mittee were unanimous in their opinion that both 
frequency of operation and outcome of a surgical 
sample were important parameters in judging an 
applicant's competence. The committee decided that 
12 CEAs per year per surgeon was the minimum 
acceptable number. The committee also was influ- 
enced by a report from the American Heart Associa- 
tion that set acceptable limits for morbidity and 
mortality rates as a function of indication for 
operation, s Specifically, the Surgical Management 
Committee stated that operations performed by a 
given surgeon must carry a combined strokc plus 
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mortality rate of _ 3.0% for asymptomatic patients 
and _< 5.0% for all clinical indications. Only appli- 
cants whose results met these defined criteria were 
accepted; those whose results were inferior to the 
defined criteria were not approved. If an institution 
was unable to provide asurgeon who met the defined 
criteria, that institution could not be an ACAS trial 
center. 
The Surgical Management Committee also rec- 
ognized that a sample of 50 previous cases might not 
be sufficient to accurately reflect a surgeon's current 
operative morbidity and mortality rates, and for that 
reason the committee advised that a continuing 
performance audit be built into the study design. If 
an institution reported apostoperative complication 
of either death or stroke after the study commenced, 
that center was to be placed on a "watch" stares. If a 
second postoperative complication occurred, an in- 
stitutional audit would be triggered. This would 
include a re-review of both the institutional and 
individual surgeon's results to determine whether the 
individual or the entire institution should be sus- 
pended from the study because of an unacceptably 
high complication rate. 
The cumulative data from this audit and selection 
process were reviewed in February i991 before 
publication of the initial description of the method. 
One hundred sixty-four surgeons from 48 centers 
applied for ACAS approval. At that time, 117 
applicants from 38 of the 39 ACAS centers that 
ultimately participated were approved. Ninety-eight 
of the 117 approved surgeons were general vascular 
surgeons and i9 were neurosurgeons. Seventeen 
surgeons were not approved. Thirty did not complete 
the application process. The basis for rejection 
included < I2 operations per year or an unacceptably 
high morbidity and mortality rate demonstrated by
the review process. 4 
The 117 approved ACAS surgeons ubmitted 
5641 CEAs for review. The average number of CEAs 
performed annually by each surgeon was 20. The 
distribution of operations as a function of clinical 
indication was as follows: 1511 operations (26.8%) 
in asymptomatic patients (mortality rate, 0.8%; 
stroke morbidity rate, 0.9%); 3034 (53.8%) in 
patients with symptoms of transient cerebral isch- 
emia (mortality rate, 0.5%; stroke morbidity rate, 
1.8%); 1096 (19.4%) in patients with a history of 
stroke (mortality rate, 1.6%; stroke morbidity rate, 
1.9%). The overall mortality and stroke morbidity 
rates for all indications and all surgeons were 0.8% 
and 1.5%, respectively. 
The Data, Safety, and Monitoring Committee 
was instructed by the NINDS-approved protocol to 
stop the study if the aggregate morbidity and 
mortality rate associated with CEA exceeded 3.0%. 
During the course of the ACAS trial, only three 
institutions reported a second complication resulting 
in an institutional review. No surgeon or institution 
was dropped from the ACAS trial because of an 
unacceptably high complication rate. During the 
course of the study, the Surgical Management 
Committee and the other participants did not know 
the overall operative morbidity and mortality rate, 
but assumed that it must be under 3.0% because the 
study had not been stopped. Thus the ultimate 
validation of the surgeon selection process awaited 
the completion of the study and release of the results, 
including the data concerning operative morbidity 
and mortality rates. 
RESULTS 
ACAS trial outcome. Between December 1987 
and December 1993, 1662 patients were entered in 
the study and randomized to the surgical or medical 
treatment arm. At the time of study analysis, 
follow-up data were available on 1659 patients. Eight 
hundred thirty-four patients were randomized tobest 
medical management, including aspirin and risk- 
factor control. Eight hundred twenty-five patients 
were randomized toCEA plus best medical manage- 
ment. The design of the study was intent-to-treat, 
and therefore the patient randomized to one arm of 
the study carried that study designation regardless of 
whether a crossover occurred. 
On September 14, 1994, the study was formally 
stopped because the Data, Safety, and Monitoring 
Committee indicated a significant boundary had been 
crossed in favor of surgical management. The study 
centers and the patients who had been randomized to
medical management were notified so that hey could 
be evaluated for the opportunity to undergo surgery 
if they were still good surgical candidates. 
The 5-year cumulative stroke risk for patients 
randomized to the surgical arm (including perioper- 
ative stroke and death) was 5.1%; in contrast, the 
5-year stroke risk in the patients randomized to the 
medical treatment arm was 11%. CEA provided an 
absolute risk reduction of 5.9% and a relative risk 
reduction of 53% (p = 0.004).1,2 
Analysis of surgery data. Eight hundred twenty- 
five patients were randomized to the surgical arm. 
Nineteen patients had a stroke or died within 30 days 
of randomization, yielding a combined stroke mor- 
bidity and mortality rate of 2.3% (95% confidence 
interval, 1.3% to 3.3%). Not all patients, however, 
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Table I. Reasons urgery was not performed 
Reason Pa~ent (no.) 
45 Refused operation 
Ineligible for operation 
Angiogram showed stenosis < 60% after randomization 
Cardiac status contraindicated operation 
Finding of an intracranial stenosis of greater severity 
Stroke or death before operation 
Miscellaneous reasons 
Total 
27 
12 
6 
3 
8 
101 
underwent surgery. In addition, not all deaths and 
complications occurred as a consequence of surgery. 
Nonetheless, in an intent-to-treat nalysis all patients 
randomized to surgery are counted as the surgical 
group, and all complications occurring within the 
surgical group are debited against surgery. 
Of the 825 patients randomized to the surgical 
arm, 101 did not receive CEA (Table 1). Of the 19 
patients in the surgical arm who had a stroke or died, 
two strokes and one death occurred before surgery. 
Four strokes, one leading to death, occurred as 
complications of preoperative arteriography. Ten 
strokes and one fatal myocardial infarction occurred 
within 30 days of CEA. Therefore, of the 724 
patients in whom CEA was performed, 10 had 
strokes within 30 days, yielding a 1.38% stroke rate; 
and one died within 30 days, yielding a 0.14% 
mortality rate, for a combined stroke morbidity and 
mortality rate of 1.52% (95% CI, 0.6% to 2.4%). 
Three hundred ten of the 724 patients who un- 
derwent CEA had an arteriogram performed before 
randomization. Four hundred fourteen patients un- 
derwent arteriography after randomization but be- 
fore surgery. The arteriograms were complicated by 
four strokes and one death from stroke after anglo- 
grams, which yielded a combined stroke morbidity 
and mortality rate from arteriography of 1.2%. 2 
DISCUSSION 
For CEA to be an effective form of stroke 
prevention in asymptomatic patients, it must reduce 
the risk 'of clinically important neurologic events 
when compared with medical management alone. 
The risk of surgery in terms of neurologic omplica- 
tion and death must be sufficiently low as to not erase 
the benefit of plaque removal. Previous tudies have 
achieved the first objective but were unable to achieve 
the second. For example, the first trial that compared 
a surgical and medical method was reported by the 
Joint Study of Extracranial Arterial Occlusive Dis- 
ease. This study, begun in 1959, ultimately random- 
ized 1225 patients;621 were randomized to CEA, 
and 604 were treated with what was then the best 
medical management. 
A statistically significant benefit in survival rate 
was seen among those treated surgically rather than 
those treated medically. Three hundred sixteen pa- 
tients entered the study and were identified as having 
transient ischemic attacks without residual deficit. 
The incidence of subsequent transient ischemic 
attacks or cerebral infarction was lower in the surgical 
group than in the medical group. When the periop- 
erative morbidity and mortality rate of 8% was 
factored in, however, the difference lost statistical 
significance. 6 If these trial data had been associated 
with the modern low risk of surgery, subsequent 
symptomatic trials may not have been required to 
establish efficacy of surgery. More recently, the 
Veterans Affairs trial involving asymptomatic pa- 
tients was designed to compare the endpoints of 
transient ischemic attack, stroke, and death among 
patients randomized to prophylactic CEA compared 
with those treated with medical management alone. 
The outcome clearly favored CEA. When an attempt 
was made to evaluate the endpoint of stroke alone 
(which the trial was not designed to do), twice as 
many strokes were found in the medical group as in 
the surgical group. When the perioperative mortality 
rate was added, however, this fell just short of 
statistical significance. 7 In contrast, the ACAS trial, 
with a combined surgical neurologic morbidity and 
mortality rate of 1.52% of those who underwent 
surgery, and even with a morbidity and mortality rate 
of 2.3% including preoperative arteriographic and 
other causes of stroke and death, permitted a 
statistically significant benefit in favor of surgery 
when compared with medical management. This 
benefit occurred espite the relatively low event rate 
in the medically managed group of 2.2% per year, or 
11.0% overall in 5 years. 
The method described for selecting surgeons to 
participate in the ACAS trial appears to have been 
uniquely successful. The selection process for sur- 
geons was based upon a retrospective audit of their 
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results for CEA. The aggregate r trospective analysis 
for surgeons elected to participate in ACAS docu- 
mented that the surgeons had performed CEA in 
asymptomatic patients with a combined stroke and 
mortality rate of 1.7%. The ultimate validation of any 
method of selection, however, must depend on the 
surgical performance of the surgeons examined 
prospectively. In that analysis, the surgeons elected 
performed extremely well, exhibiting a combined 
stroke and mortality incidence of 1.52%, which was 
remarkably similar to the retrospective audit data. 
The Surgical Management Committee made a 
specific point of not mandating a particular technique 
or series of  techniques in performing CEA. The 
committee recognized legitimate variations for per- 
forming the operation and held that surgical results 
were the ultimate factor in determining which 
technique a surgeon chose. Therefore, these excellent 
results were achieved with a variety of  techniques, 
emphasizing the fact that surgeons who perform 
quality work do best when they are permitted to 
choose the technique that they have used successfully. 
Clinical application of the results of ACAS into 
everyday practice requires proper patient selection 
and careful screening of the surgeons performing this 
elective procedure. In ACAS it was only by requiring 
extensive xperience with a proven track record of  
< 3.0% morbidity and mortality for CEA in asymp- 
tomatic patients that we were able to prove a benefit 
for the operation. Any deviation upward for the mor- 
bidity and mortality rates, even to the "acceptable" 
levels found in the Veterans Affairs Cooperative 
Study, would have caused ACAS to lose its significant 
benefit in favor of surgery. We recommend that be- 
fore referring patients for asymptomatic CEA, the 
referring doctor should ensure that the surgeon has 
experience and a track record comparable with those 
reported in ACAS. 
CONCLUSION 
The technique for selecting surgeons to partici- 
pate in CEA trials may serve as a model for future 
trials of CEA or future trials involving any other 
surgical method. It may also serve as a model for 
hospital committees evaluating surgical privileges for 
performance of CEA. Methods of auditing surgeons' 
performance have been previously published and 
correspond well with the outcome of the study based 
on prestudy surgeon selection, s'9 
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APPENDIX  I: SURGICAL  MANAGEMENT 
COMMITTEE 
Wesley S. Moore, MD, Chairman 
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Richard Dean, MD 
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APPENDIX  II. PART IC IPAT ING 
INST ITUT IONS AND ACAS-APPROVED 
SURGEONS IN THE ACAS STUDY ~ 
Barrow Neurological Institute at St. Joseph's Hospital and 
Medical Center, Phoenix: Robert F. Spetzler, Joseph 
M. Zabramski 
Bowman Gray School of Medicine at Wake Forest Uni- 
versity, Winston-Salem, N.C.: Charles L. Branch, 
Robert Cordell, Richard Dean, Arthur Edgerton, J.
Michael McWhorter, George Plonk 
*After the initial review in February 1991, an additional 11 
surgeons were reviewed and approved by the same process, 
bringing the total listing to 128. It should be noted that 103 of 
the 128 approved surgeons contributed tothe ACAS trial. 
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• California Pacific Medical Center, San Francisco: Charles 
Gould, Robert Szarnicki 
Cleveland Clinic: Isam Awad, John Little 
Columbia University, New York: James Correll, Donald 
Quest 
Harbin Clinic, Rome, Ga.: John S. Kirkland, Leon 
Rhodes, Michael Rogers 
Henry Ford Hospital, Detroit: Joseph P. Elliot Jr., Calvin 
B. Ernst, Daniel J. Red@, Alexander D. Shepard, 
Roger F. Smith 
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Medical College of Virginia (Virginia Commonwealth 
University), Richmond: Guy Clifton, H.M. Lee, Marc 
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Milton S. Hershey Medical Center, Hershey, Pa.: Robert 
G. Atnip, Brian L. ThMe 
New England Medical Center, Boston, Mass.: Michael 
Belkin, William C. Mackey, Thomas O'Donnell 
Northwestern University Medical School, Chicago: Doug- 
las Chyatte, Walter McCarthy, William Pearce, James 
Yao 
Ochsner Clinic, New Orleans: John Bowen, Larry Hollier, 
John Ochsner 
Oregon Health Sciences University, Portland: Gregory 
Moneta, John Porter, Lloyd Taylor, Richard Yeager 
Roanoke Neurological Associates, Roanoke, Va.: Jesse T. 
Davidson II, Edwin L. Williams II 
Singing River Hospital, Pascagowa, Miss.: Dewey H. Lane 
St. John's Mercy Medical Center, St. Louis: ArNur Auer, 
Joseph Hurley, Richard Pennell, John Woods 
Sunnybrook Health Science Centre, North York, Ont.: 
David Rowed 
University Hospital, London, Ont.: Gary Ferguson, 
Stephen Lownie, S.J. Peerless, Howard Reichman 
University of Arizona Health Sciences Center, Tucson: 
Victor M. Bernhard, L. Philip Carter, Glenn C. 
Hunter, Kenneth E. McIntyre 
University of Arkansas Center for Medical Sciences, Little 
Rock: Robert W. Barnes, Gary W. Barone, John F. 
Eidt, Bernard W. Thompson 
University of California, Los Angeles: Samuel S. Alan, J. 
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